_id,from_id,to_id,properties
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:0,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7160,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Glioblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7170,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Systemic lupus erythematosus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""70"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:5,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:6,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7186,"{""doseUnit"": ""IU"", ""route"": ""Intravenous drip"", ""doseAmount"": ""3600"", ""indication"": ""Gaucher's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7187,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Basal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:10,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:11,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:12,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:13,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:15,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:16,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:17,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:18,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:19,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:20,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:21,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:22,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:23,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:24,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:25,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:26,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:27,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:28,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:29,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:30,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:31,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:32,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:33,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:34,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Post herpetic neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:35,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:36,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:37,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""0.99"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""1.5"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:43,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:44,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""150"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:45,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:46,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:47,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:48,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.25"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:49,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:50,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:51,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:52,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7243,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.8"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:53,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:54,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7248,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Gait disturbance"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:55,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""225"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:56,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:57,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:59,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:60,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG/KG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:61,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:62,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:63,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:64,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:65,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:66,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:67,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.625"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:68,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:69,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:70,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:71,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38520,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:72,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:73,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7288,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Partial lipodystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:74,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:75,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:76,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:77,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:78,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7291,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Basal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:79,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:80,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:81,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Nerve injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:82,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Paralysis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:83,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:84,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:85,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:86,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:87,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:88,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:89,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:90,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7305,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:91,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:92,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:93,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:94,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:95,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:96,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:97,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:98,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:99,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7314,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""7"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7288,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.5"", ""indication"": ""Partial lipodystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7321,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Lupus nephritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7288,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7.5"", ""indication"": ""Non-alcoholic steatohepatitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38585,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7351,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.25"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.97"", ""indication"": ""Chemotherapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7356,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7357,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7359,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""14"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Thrombosis prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Drug dependence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7401,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""56"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7415,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7432,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Chronic myeloid leukaemia recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7438,"{""doseUnit"": ""UG/KG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.08"", ""indication"": ""Heritable pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38643,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7444,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""250"", ""indication"": ""Light anaesthesia"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7446,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""8.4"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""1.5"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7291,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Ovarian epithelial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7460,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Mucopolysaccharidosis VI"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7469,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4"", ""indication"": ""Juvenile idiopathic arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7472,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""DF"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Acute lymphocytic leukaemia recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""37.5"", ""indication"": ""Metastatic renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Paraesthesia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7469,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""8"", ""indication"": ""Takayasu's arteritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7490,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Menopause"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Rosai-Dorfman syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7248,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7188,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7526,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7530,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Hypophysectomy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Intervertebral disc degeneration"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7541,"{""doseUnit"": ""MG"", ""route"": ""Transplacental"", ""doseAmount"": ""8"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Primary progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7571,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7325,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Flatulence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7611,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Mucopolysaccharidosis IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7162,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Anxiety"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.4"", ""indication"": ""Neuroblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7634,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""180"", ""indication"": ""HER2 positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7646,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Dyslipidaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7451,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""40"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Langerhans' cell histiocytosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7669,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""6""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Erdheim-Chester disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7401,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""56"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7686,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""250"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""145"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7687,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Insulin-like growth factor increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7688,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""160"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7695,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""22.5"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Routine health maintenance"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""124"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""141"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""116"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""148"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""134"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""140"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""138"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7715,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Mycobacterium avium complex infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Alveolar soft part sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""124"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7733,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Bronchial carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""131"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7739,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""1.53"", ""indication"": ""Hot flush"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Langerhans' cell histiocytosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7687,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Insulin-like growth factor increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7371,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""12""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7160,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Astrocytoma, low grade"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7199,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7759,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Colon cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7451,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""8"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7764,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7766,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Thrombosis prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""197"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7783,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.4"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7787,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""37.5"", ""indication"": ""Agoraphobia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""22"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7537,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""737.5"", ""indication"": ""Ovarian cancer stage III"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3.1"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7766,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7271,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7817,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""0.3"", ""indication"": ""Macular degeneration"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7687,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Acromegaly"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Neurodermatitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Sciatica"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Sciatica"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7268,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Blood pressure abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Cholangiocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""37.5"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7851,"{""doseUnit"": ""MG"", ""route"": ""Topical"", ""doseAmount"": ""30"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.6"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""G"", ""route"": ""Vaginal"", ""doseAmount"": ""1"", ""indication"": ""Cystitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""278"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.625"", ""indication"": ""Bone disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7863,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.025"", ""indication"": ""Menopause"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7874,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2235"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7571,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7851,"{""doseUnit"": ""MG"", ""route"": ""Topical"", ""doseAmount"": ""30"", ""indication"": ""Androgen deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1309"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7537,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7884,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Cystitis interstitial"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7886,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7553,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Hiatus hernia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7359,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7683,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Colon cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7893,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7537,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""4""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7896,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""61"", ""indication"": ""Cardiac amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""135"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38942,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7243,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.8"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""240"", ""indication"": ""Hepatic cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Incontinence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""25"", ""indication"": ""Pollakiuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""82"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7914,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Pollakiuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7919,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""267"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7920,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7922,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""158.2"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""180"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7736,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""123"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""143"", ""indication"": ""Invasive ductal breast carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""143"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""142"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""130"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38974,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7698,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7736,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""130"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7688,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""160"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7930,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""80"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""4.35"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7939,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3.6"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Restless legs syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7245,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:643,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7944,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:38999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7945,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""12"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""400"", ""indication"": ""Headache"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""110"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Spinal stenosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7951,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.75"", ""indication"": ""Neoplasm"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39005,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39006,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Secondary progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7954,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""38"", ""indication"": ""Metastatic neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Post procedural hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Nervous system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""180"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""On and off phenomenon"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7190,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""3.1"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1800"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""80"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Post procedural hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Cholangiocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""260"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7975,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Peripheral T-cell lymphoma unspecified"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""257"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7359,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""160"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""45"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7505,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""225"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7983,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""450"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7984,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Chronic spontaneous urticaria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7896,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""61"", ""indication"": ""Cardiac amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7.5"", ""indication"": ""Combined immunodeficiency"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""140"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39060,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8003,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Constipation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""12"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""170.1"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8012,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8013,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""70"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""120"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""140"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8027,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Myelofibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""280"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Hypocalcaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Peripheral T-cell lymphoma unspecified refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7715,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Mycobacterium abscessus infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""8.4"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8047,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""760"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8054,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis relapse"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.14"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12.5"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""32"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4328"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""280"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7874,"{""doseUnit"": ""IU"", ""route"": ""Intravenous drip"", ""doseAmount"": ""2500"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Polymyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8069,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-24-hour sleep-wake disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8069,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-24-hour sleep-wake disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8069,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-24-hour sleep-wake disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7163,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8086,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""150"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.09"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7893,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""250"", ""indication"": ""Vascular malformation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.93"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""360"", ""indication"": ""Transitional cell cancer of renal pelvis and ureter metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7919,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""267"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Metastatic uterine cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""130"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Combined immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8091,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""80"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""27"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7783,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Immune reconstitution inflammatory syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""67.5"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8097,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""90"", ""indication"": ""Iron overload"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8098,"{""doseUnit"": ""MG"", ""route"": ""Vaginal"", ""doseAmount"": ""2"", ""indication"": ""Urinary tract infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""165"", ""indication"": ""Invasive ductal breast carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""85"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8114,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1500"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8119,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Thyroid cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7190,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8123,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""19.96"", ""indication"": ""Nausea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8124,"{""doseUnit"": ""MG"", ""route"": ""Intrathecal"", ""doseAmount"": ""15"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8126,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8132,"{""doseUnit"": ""MG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""6.1"", ""indication"": ""Ischaemic stroke"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.318"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Angiosarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""160"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8150,"{""doseUnit"": ""350"", ""route"": ""INFLIXIMAB"", ""doseAmount"": ""Intravenous (not otherwise specified)"", ""indication"": ""MG"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8151,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""600"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7467,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7539,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""530"", ""indication"": ""Triple negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3387"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia stage 4"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Paraesthesia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""33"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8167,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8172,"{""doseUnit"": ""DF"", ""route"": ""Respiratory (inhalation)"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7571,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""30"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8184,"{""doseUnit"": ""ML"", ""route"": ""Respiratory (inhalation)"", ""doseAmount"": ""2.5"", ""indication"": ""Cystic fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Bladder cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.54"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Selective IgA immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8063,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""DF"", ""route"": ""Other"", ""doseAmount"": ""0.35"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""280"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8201,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""61"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7300,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Back pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Polychondritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7356,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8"", ""indication"": ""Calculus urinary"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Selective IgM immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""240"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Transient hypogammaglobulinaemia of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""300"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39300,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Triple positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8218,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3.6"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Unknown"", ""doseAmount"": ""1000"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39311,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""55"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8123,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1000"", ""indication"": ""Glycogen storage disease type II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Uterine leiomyoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7356,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Pollakiuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8228,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""68"", ""indication"": ""Diffuse large B-cell lymphoma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Spinal stenosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""34"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.3"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.2"", ""indication"": ""Growth disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""113"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""19"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3.5"", ""indication"": ""Prader-Willi syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7930,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""320"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Weight decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""120"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8138,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Cystic fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Triple negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8235,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""HIV wasting syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Sciatica"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""90"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1060,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7520,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""185"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8236,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Hormone receptor positive HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7813,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Pneumonia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8241,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Lung adenocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8243,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""50"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.5"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8248,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Mesothelioma malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7332,"{""doseUnit"": ""MG"", ""route"": ""Intrathecal"", ""doseAmount"": ""15"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8252,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Embryonal rhabdomyosarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""312"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""25"", ""indication"": ""Urge incontinence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8156,"{""doseUnit"": ""UG"", ""route"": ""Intrathecal"", ""doseAmount"": ""930"", ""indication"": ""Muscle spasticity"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8156,"{""doseUnit"": ""UG"", ""route"": ""Intrathecal"", ""doseAmount"": ""440"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3788"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8069,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-24-hour sleep-wake disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.325"", ""indication"": ""Diarrhoea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""120"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8119,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Thyroid cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.1"", ""indication"": ""Dwarfism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""28"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""37.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8285,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""550"", ""indication"": ""Liver disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8291,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""26"", ""indication"": ""B precursor type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""22"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""500"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8298,"{""doseUnit"": ""ML"", ""route"": ""INTRACAVITY"", ""doseAmount"": ""1"", ""indication"": ""Erectile dysfunction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39414,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8299,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""160"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8300,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""22.5"", ""indication"": ""Precocious puberty"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7531,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Hypothyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8285,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""550"", ""indication"": ""Hepatic encephalopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Stiff person syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7296,"{""doseUnit"": ""ML"", ""route"": ""Topical"", ""doseAmount"": ""1"", ""indication"": ""Alopecia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7905,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""162"", ""indication"": ""Giant cell arteritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""350"", ""indication"": ""Psychotic disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Back disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""42.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.3"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8323,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Erectile dysfunction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8092,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Weight decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.6"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7300,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""70"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Pleural mesothelioma malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7466,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""105"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""55"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8340,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7893,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Coeliac disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8348,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""30"", ""indication"": ""Chemotherapy"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Hypothalamo-pituitary disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Growth failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16.6"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""280"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""27"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""21"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Encephalitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8352,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Dizziness"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7748,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""30"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8353,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""267"", ""indication"": ""Benign neoplasm of prostate"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8285,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""550"", ""indication"": ""Hepatic cirrhosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Blood growth hormone"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8360,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8367,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""32"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""5q minus syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Stiff person syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8378,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""45"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39520,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""120"", ""indication"": ""Polymyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7458,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""3"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3.4"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""17.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8381,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Serum ferritin decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Pyrexia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7905,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8115,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Essential thrombocythaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""13"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""16"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7922,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8387,"{""doseUnit"": ""GTT"", ""route"": ""Ophthalmic"", ""doseAmount"": ""1"", ""indication"": ""Neurotrophic keratopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.8"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8143,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""25"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8388,"{""doseUnit"": ""PCT"", ""route"": ""Rectal"", ""doseAmount"": ""1"", ""indication"": ""Intestinal haemorrhage"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Dermatomyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""32"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""55"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Lumbar radiculopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""DiGeorge's syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7411,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""820"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.9"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""7"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8404,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Weight decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7689,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Combined immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8201,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""61"", ""indication"": ""Cardiac amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1311,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""13"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.2"", ""indication"": ""Autoimmune disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39585,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8414,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2400"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Selective IgA immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8415,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.1"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.3"", ""indication"": ""Food allergy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7187,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Basal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1700"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1900"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2300"", ""indication"": ""Muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1300"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""800"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2900"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2000"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2200"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1500"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""9"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Squamous cell carcinoma of the cervix"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8427,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8400,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7.2"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""180"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8432,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""0.3"", ""indication"": ""Hypersensitivity"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""0.99"", ""indication"": ""Lipidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma in remission"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Endometriosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8434,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Infective pulmonary exacerbation of cystic fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8416,"{""doseUnit"": ""DF"", ""route"": ""Intramuscular"", ""doseAmount"": ""1"", ""indication"": ""Food allergy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""34"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""9"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8047,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""650"", ""indication"": ""Plasma cell myeloma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8446,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39643,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8450,"{""doseUnit"": ""DF"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""1.6"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""90"", ""indication"": ""Lung carcinoma cell type unspecified stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8471,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7315,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Joint injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.5"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8040,"{""doseUnit"": ""UG"", ""route"": ""Intramuscular"", ""doseAmount"": ""30"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Back pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8483,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7733,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8487,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8489,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Long-chain acyl-coenzyme A dehydrogenase deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Bone cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Polyneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""480"", ""indication"": ""Gastric cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""480"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8501,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""68"", ""indication"": ""B-cell type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Left ventricular failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""360"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7291,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Squamous cell carcinoma of the tongue"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8156,"{""doseUnit"": ""UG"", ""route"": ""Intrathecal"", ""doseAmount"": ""37.006"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8387,"{""doseUnit"": ""GTT"", ""route"": ""Ophthalmic"", ""doseAmount"": ""1"", ""indication"": ""Keratitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7539,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""220"", ""indication"": ""Cervix carcinoma stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""12"", ""indication"": ""Mucopolysaccharidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8507,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Smoking cessation therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8508,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""12"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""180"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8510,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""130"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Neck pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8513,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8509,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""450"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Alveolar soft part sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""7"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8515,"{""doseUnit"": ""DF"", ""route"": ""Transdermal"", ""doseAmount"": ""1"", ""indication"": ""Menopausal symptoms"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7537,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1358"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8054,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2000"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8241,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Synovial sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8517,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""6"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""19"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5.5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7905,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""162"", ""indication"": ""Giant cell arteritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""240"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7687,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Acromegaly"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""360"", ""indication"": ""Metastatic renal cell carcinoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""DF"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8535,"{""doseUnit"": ""DF"", ""route"": ""Vaginal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4.437"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""27.5"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""225"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8538,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Immune thrombocytopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7201,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""0.65"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8388,"{""doseUnit"": ""PCT"", ""route"": ""Rectal"", ""doseAmount"": ""1"", ""indication"": ""Haemorrhoids"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""0.24"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""80"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8381,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Iron deficiency anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""24"", ""indication"": ""Mucopolysaccharidosis II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""179.4"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""0.492"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8547,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.35"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.8"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.6"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Polymyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""4.5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.24"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8201,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""61"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Primary amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8551,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""700"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8552,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""80"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8553,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Toxic goitre"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8554,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1790"", ""indication"": ""Peripheral T-cell lymphoma unspecified"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8553,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""800"", ""indication"": ""Basedow's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Combined immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Multiple sclerosis relapse"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8558,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.5"", ""indication"": ""Type 1 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8559,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Autoimmune thyroiditis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8560,"{""doseUnit"": ""DF"", ""route"": ""Transplacental"", ""doseAmount"": ""1"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8510,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""134.4"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.6"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8487,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4200"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.13"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7354,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""85"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8471,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Axial spondyloarthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7472,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG/KG"", ""route"": ""Unknown"", ""doseAmount"": ""0.05"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""36"", ""indication"": ""Mucopolysaccharidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""14"", ""indication"": ""Metastatic renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Cervix carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8586,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG/KG"", ""route"": ""Unknown"", ""doseAmount"": ""0.05"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""120"", ""indication"": ""Metastasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8587,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2000"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1200"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""180"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Uterine leiomyoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8299,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""320"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""201.9"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunoglobulins abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Multifocal motor neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8603,"{""doseUnit"": ""ML"", ""route"": ""IRRIGATION"", ""doseAmount"": ""4"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Major depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""120"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8299,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""302"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8606,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8513,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.7"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.54"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8388,"{""doseUnit"": ""PCT"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Haemorrhoids"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Dermatomyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.25"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8236,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8299,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""320"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8476,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""320"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8553,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1614"", ""indication"": ""Toxic goitre"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""12""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8619,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.86"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""110"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""22"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""1.4"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""0.8"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""5.9"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8623,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Fallopian tube cancer stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""180"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Fallopian tube cancer stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7248,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Gait disturbance"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1232"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8636,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5.4"", ""indication"": ""HER2 positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Rectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8154,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8640,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7504,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8645,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""450"", ""indication"": ""Antiviral prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8646,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Colorectal cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Squamous cell carcinoma of head and neck"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Primary progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Fall"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8483,"{""doseUnit"": ""ML"", ""route"": ""Other"", ""doseAmount"": ""100"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Oestrogen receptor assay positive"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8649,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Colorectal adenocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7539,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""750"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""5""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8247,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8651,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Benign prostatic hyperplasia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Uterine fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""190"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""190"", ""indication"": ""Sickle cell anaemia with crisis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8654,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Pituitary tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8416,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""0.3"", ""indication"": ""Hypersensitivity"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39942,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8401,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8655,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""11"", ""indication"": ""Magnetic resonance imaging"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8551,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8621,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8660,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""102"", ""indication"": ""Haemophilia A without inhibitors"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Rectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""0.5"", ""indication"": ""Mucopolysaccharidosis II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7188,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.8"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Colorectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""65"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8672,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1250"", ""indication"": ""Hormone receptor positive HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Juvenile idiopathic arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8054,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""110"", ""indication"": ""Polyneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""8.4"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8680,"{""doseUnit"": ""IU"", ""route"": ""Intramuscular"", ""doseAmount"": ""50"", ""indication"": ""Skin wrinkling"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39974,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.75"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Drug dependence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8691,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Adenocarcinoma of colon"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""30"", ""indication"": ""Acute lymphocytic leukaemia recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8544,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8381,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Iron deficiency anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8241,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Colon cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:39999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8727,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""37.5"", ""indication"": ""Post-traumatic stress disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7170,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""80"", ""indication"": ""Systemic lupus erythematosus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40005,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""120"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40006,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Secondary progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8055,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""225"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8368,"{""doseUnit"": ""MG/KG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Anaemia of malignant disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7234,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7882,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7905,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""162"", ""indication"": ""Giant cell arteritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Haematological malignancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8739,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Angioimmunoblastic T-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8748,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8143,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7539,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""384.5"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7321,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""750"", ""indication"": ""Renal transplant"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell anaemia with crisis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7213,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8655,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Pruritus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8764,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.2"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""White blood cell disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.23"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8098,"{""doseUnit"": ""DF"", ""route"": ""Vaginal"", ""doseAmount"": ""1"", ""indication"": ""Atrophic vulvovaginitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8388,"{""doseUnit"": ""PCT"", ""route"": ""Rectal"", ""doseAmount"": ""1"", ""indication"": ""Haemorrhoids"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.8"", ""indication"": ""Body height abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8768,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Primary biliary cholangitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""150"", ""indication"": ""Philadelphia positive acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8353,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""267"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""170"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7181,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40060,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8236,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8387,"{""doseUnit"": ""GTT"", ""route"": ""Ophthalmic"", ""doseAmount"": ""1"", ""indication"": ""Neurotrophic keratopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8774,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Mucopolysaccharidosis II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""290"", ""indication"": ""Adrenocortical carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8551,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.23"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""32"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Leiomyosarcoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8785,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""480"", ""indication"": ""Infection prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8786,"{""doseUnit"": ""MG"", ""route"": ""Transplacental"", ""doseAmount"": ""500"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""245"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Neuroendocrine tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8473,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""3"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Cardiac failure congestive"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7897,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8790,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Brain neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.8"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Colorectal cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8794,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Osteoporosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""325"", ""indication"": ""Schizoaffective disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Colorectal cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""3.5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG/KG"", ""route"": ""Unknown"", ""doseAmount"": ""0.05"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1942,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8801,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8803,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8806,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""7000"", ""indication"": ""Factor IX deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Colon cancer stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8807,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""14"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8218,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Connective tissue disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7920,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.6"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.45"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7922,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8810,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""17.5"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8811,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Liposarcoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8812,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8814,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""14"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8143,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.272"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7893,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""PIK3CA related overgrowth spectrum"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1974,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7922,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""32"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Clinically isolated syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8823,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Epilepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8551,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8825,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Invasive breast carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8830,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Chronic hepatitis C"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""181.5"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8551,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:1999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Thrombosis prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8845,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Prostate cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""180"", ""indication"": ""Neurofibromatosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Turner's syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8846,"{""doseUnit"": ""MCI"", ""route"": ""Unknown"", ""doseAmount"": ""202.47"", ""indication"": ""Carcinoid tumour of the duodenum"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8064,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""150"", ""indication"": ""Philadelphia positive acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Adenocarcinoma of colon"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""14"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8748,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""800"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7788,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Chemotherapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Skin cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""90"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7905,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""162"", ""indication"": ""Giant cell arteritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8855,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Seronegative arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8691,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Deep vein thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8810,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""17.5"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Other"", ""doseAmount"": ""0.45"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8858,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""42"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8859,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7893,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""32"", ""indication"": ""Familial mediterranean fever"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8862,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""165"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8236,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Squamous cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8870,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""675"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""120"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8872,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""500"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8764,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8873,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""14"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Adenocarcinoma of colon"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8489,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Carnitine palmitoyltransferase deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Hypothyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8817,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Iron deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7939,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3.6"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8880,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Gastrointestinal carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""520"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""840"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Metastatic neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8884,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Skin ulcer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8885,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""6"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""4.9"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8465,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""2.7"", ""indication"": ""Lennox-Gastaut syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8201,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8886,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""23.7"", ""indication"": ""Lupus nephritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""560"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8889,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8892,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Colorectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8896,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""44"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1.5"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8900,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Muscular weakness"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Colon cancer stage III"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8748,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8902,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Triple negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8904,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Endometriosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8905,"{""doseUnit"": ""MG/KG"", ""route"": ""Intramuscular"", ""doseAmount"": ""15"", ""indication"": ""Trisomy 21"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8119,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Thyroid cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8907,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""123"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Renal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8908,"{""doseUnit"": ""GTT"", ""route"": ""Ophthalmic"", ""doseAmount"": ""1"", ""indication"": ""Blepharitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""90"", ""indication"": ""Lung squamous cell carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8858,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""42"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Bladder cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""280"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8911,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""80"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""800"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40300,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8489,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Long-chain acyl-coenzyme A dehydrogenase deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""DF"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""196"", ""indication"": ""Epithelioid mesothelioma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7940,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous drip"", ""doseAmount"": ""375"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8918,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8921,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""45"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.75"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40311,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8034,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""137"", ""indication"": ""Dyskinesia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8926,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Urinary tract infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""275"", ""indication"": ""Sickle cell anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8810,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""17.5"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.7"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Malignant peritoneal neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7170,"{""doseUnit"": ""MG/KG"", ""route"": ""Transplacental"", ""doseAmount"": ""10"", ""indication"": ""Systemic lupus erythematosus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8928,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""120"", ""indication"": ""Hypophosphatasia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8929,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Magnetic resonance imaging abdominal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7354,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.8"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Drug dependence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7411,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8934,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Soft tissue neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8204,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""500"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8941,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Papillary thyroid cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""41"", ""indication"": ""Chordoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Carcinoid tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8558,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.25"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Chronic kidney disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8404,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Weight decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7505,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Nerve compression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8367,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8812,"{""doseUnit"": ""MG/M**2"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Nephroblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8948,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Lysosomal acid lipase deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8500,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""208"", ""indication"": ""Leiomyosarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8950,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""62.5"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8958,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""170"", ""indication"": ""Recurrent cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8964,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8098,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Menopausal symptoms"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8965,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""4""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7183,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""6.25"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""889.2"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8381,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Iron deficiency anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Prostate cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8967,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8552,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Psychotic disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8970,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8143,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""520"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8976,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1297.5"", ""indication"": ""Haematological malignancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""120"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous drip"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1680"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8660,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""175.8"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8291,"{""doseUnit"": ""UG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""B precursor type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8985,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""465"", ""indication"": ""Myelosuppression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8991,"{""doseUnit"": ""MG"", ""route"": ""Cutaneous"", ""doseAmount"": ""0.5"", ""indication"": ""Skin swelling"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7922,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40414,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9003,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""0.92"", ""indication"": ""Immunosuppression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1200"", ""indication"": ""Transitional cell carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8291,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""28"", ""indication"": ""B precursor type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9005,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4.4"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7411,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2300,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9008,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""52.2"", ""indication"": ""Mucopolysaccharidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9009,"{""doseUnit"": ""ML"", ""route"": ""Intramuscular"", ""doseAmount"": ""2"", ""indication"": ""Tendonitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9009,"{""doseUnit"": ""ML"", ""route"": ""Intramuscular"", ""doseAmount"": ""1"", ""indication"": ""Tendon disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9011,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""T-cell type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9013,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""150"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9014,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Hepatitis C"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9009,"{""doseUnit"": ""ML"", ""route"": ""Intramuscular"", ""doseAmount"": ""1"", ""indication"": ""Posterior tibial nerve injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2311,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG/KG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8918,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.33"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7363,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8241,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Colon cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Recurrent cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8846,"{""doseUnit"": ""MBQ"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""7400"", ""indication"": ""Neuroendocrine tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5800"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8970,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8872,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Transplant rejection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9019,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Ovarian cancer recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""25"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8748,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Marginal zone lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7321,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""750"", ""indication"": ""Liver transplant"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9027,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Neuromyelitis optica spectrum disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8197,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""240"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7321,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1500"", ""indication"": ""Lupus nephritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7703,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""535.2"", ""indication"": ""Adenocarcinoma of colon"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8872,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""312.5"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Primary progressive multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9038,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1500"", ""indication"": ""Haemochromatosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8814,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""14"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8950,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Pancreatic carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7984,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8241,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7646,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Dyslipidaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8508,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""450"", ""indication"": ""Hairy cell leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8748,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Adenocarcinoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9043,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9044,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2.5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.75"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7456,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Weight decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary embolism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""158"", ""indication"": ""Leiomyosarcoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9048,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Migraine prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pancreatic carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40520,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8970,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8513,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7333,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""132"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2414,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8884,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Mycobacterial infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7930,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""160"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.25"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7940,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""720"", ""indication"": ""Mantle cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9065,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""80"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8489,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""1.5"", ""indication"": ""Gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""36"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8538,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9078,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Nausea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9079,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""462"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Pulmonary embolism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8154,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16000"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1800"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8646,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""HER2 positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8204,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7314,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8970,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9084,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""6"", ""indication"": ""Age-related macular degeneration"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7836,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Attention deficit hyperactivity disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9087,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""80"", ""indication"": ""Colorectal cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7585,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Hypertension"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""70"", ""indication"": ""Selective IgA immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Kaposi's sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8123,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Glycogen storage disease type II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8883,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8069,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-24-hour sleep-wake disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9091,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2400"", ""indication"": ""Gallbladder cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Non-small cell lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40585,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7225,"{""doseUnit"": ""Oral"", ""route"": "" DEXTROAMPHET SULFATE AND AMPHET SULFAT"", ""doseAmount"": ""AMPHETAMINE ASPARTATE\\AMPHETAMINE SULFATE\\DEXTROAMPHETAMINE SACCHARATE\\DEXTROAMPHETAMINE SULFATE"", ""indication"": ""30"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous drip"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9095,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9102,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7978,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""180"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""4""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8204,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""500"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7715,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Mycobacterium abscessus infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""201.6"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""960"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Pancreatic carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9112,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Sickle cell anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7920,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Deep vein thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2520,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""800"", ""indication"": ""Fallopian tube cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9116,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1500"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9011,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""900"", ""indication"": ""Plasma cell myeloma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8796,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""117"", ""indication"": ""Psychiatric symptom"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9121,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Prophylaxis against transplant rejection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.75"", ""indication"": ""Glycosylated haemoglobin increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Glioblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7940,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""679"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40643,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9127,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8365,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""45"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8517,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8204,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9044,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8389,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""24"", ""indication"": ""Colonoscopy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8340,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9134,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Haemoglobin decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9139,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Oesophageal carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7787,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""225"", ""indication"": ""Major depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.6"", ""indication"": ""Blood glucose abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9143,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""160"", ""indication"": ""Blood potassium decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9146,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8.9"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8308,"{""doseUnit"": ""Unknown"", ""route"": ""Respiratory (inhalation)"", ""doseAmount"": ""180"", ""indication"": ""Dyspnoea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2585,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7188,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""90"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Affective disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8618,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Metastatic renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG/KG"", ""route"": ""Oral"", ""doseAmount"": ""0.025"", ""indication"": ""Astrocytoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""160"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic graft versus host disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8729,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9127,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Philadelphia positive chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9009,"{""doseUnit"": ""ML"", ""route"": ""Intra-articular"", ""doseAmount"": ""1"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9154,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Erectile dysfunction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9155,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""110"", ""indication"": ""Computerised tomogram abdomen"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9155,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""110"", ""indication"": ""Computerised tomogram abdomen"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Heavy menstrual bleeding"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Colorectal cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7863,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.1"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""24"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Ovarian clear cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""390"", ""indication"": ""Colitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""800"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""80"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8132,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Cerebrovascular accident"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9161,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Insomnia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9162,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Ewing's sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""45"", ""indication"": ""Acute lymphocytic leukaemia recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""70"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.6"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8592,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Computerised tomogram abdomen"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""B-cell lymphoma refractory"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""138"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9169,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""250"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8228,"{""doseUnit"": ""DF"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7882,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""21""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6000"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8855,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8541,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.5"", ""indication"": ""Lipodystrophy acquired"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""100"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""250"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""120"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.9"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Endometrial cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Gastric cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9134,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Hormone-dependent prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8291,"{""doseUnit"": ""UG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""B precursor type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Bile duct cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""11"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8621,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""200"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9174,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1500"", ""indication"": ""Sickle cell anaemia with crisis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8884,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Mycobacterial infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8618,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8918,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Triple positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8565,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8558,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8509,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Hairy cell leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8619,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Philadelphia positive chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Trigeminal neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""12"", ""indication"": ""Growth disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7268,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""10"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8509,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""450"", ""indication"": ""Hairy cell leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8451,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.7"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""IU"", ""route"": ""Unknown"", ""doseAmount"": ""1.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Ovarian cancer recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8810,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""17.5"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""160"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Bone marrow transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8794,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Osteopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8636,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""320"", ""indication"": ""Osteosarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8901,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myasthenic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8901,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myasthenic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.75"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""480"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6000"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""420"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Ovarian epithelial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7233,"{""doseUnit"": ""UG"", ""route"": ""Intravenous bolus"", ""doseAmount"": ""200"", ""indication"": ""Nephrogenic anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9187,"{""doseUnit"": ""DF"", ""route"": ""Respiratory (inhalation)"", ""doseAmount"": ""1"", ""indication"": ""Chronic obstructive pulmonary disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Juvenile idiopathic arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""229.5"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Thrombosis prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8817,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Iron deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9048,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Migraine without aura"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7590,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7188,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.625"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""750"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8249,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9205,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9206,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.4"", ""indication"": ""Obesity"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9207,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Ovarian cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7678,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7531,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""88"", ""indication"": ""Hypothyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9212,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Irritable bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7284,"{""doseUnit"": ""UG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Analgesic therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7920,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Pulmonary embolism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9220,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.18"", ""indication"": ""Drug withdrawal syndrome"", ""drugSequence"": ""48""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7944,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7360,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7944,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9226,"{""doseUnit"": ""IU"", ""route"": ""Oral"", ""doseAmount"": ""36000"", ""indication"": ""Pancreatic failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell anaemia with crisis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9227,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Glioblastoma multiforme"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7944,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Drug use disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7247,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""800"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Skin cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Central nervous system lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.4"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9112,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8174,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""Sickle cell anaemia with crisis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""420"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7262,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Herpes zoster"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40942,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Colorectal adenocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8883,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Lung carcinoma cell type unspecified stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7519,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""166"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8896,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""44"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9236,"{""doseUnit"": ""IU/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600000"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7683,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""0.5"", ""indication"": ""Mucopolysaccharidosis II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""520"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8236,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9239,"{""doseUnit"": ""PCT"", ""route"": ""Cutaneous"", ""doseAmount"": ""5"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Non-small cell lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""85"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""360"", ""indication"": ""Bladder cancer"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5.1"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7611,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Mucopolysaccharidosis IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8812,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Hormone receptor positive HER2 negative breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8201,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""61"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7920,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9252,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40974,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7646,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""140"", ""indication"": ""Dyslipidaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8773,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7539,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""575"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""5""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Cardiomyopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Septo-optic dysplasia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""104"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""104"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.4"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Endometriosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Unknown"", ""doseAmount"": ""2500"", ""indication"": ""Angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""0.2"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""260"", ""indication"": ""Primary progressive multiple sclerosis"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""990"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:40999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.25"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41005,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3"", ""indication"": ""Turner's syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41006,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9261,"{""doseUnit"": ""MG"", ""route"": ""Sublingual"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Squamous cell carcinoma of head and neck"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""104"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""560"", ""indication"": ""Central nervous system lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous drip"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9265,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""400"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8118,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.25"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8531,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Endometrial cancer metastatic"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9267,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Malignant atrophic papulosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9268,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7476,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""14"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:2999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8747,"{""doseUnit"": ""MG"", ""route"": ""Topical"", ""doseAmount"": ""160"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7401,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Menstrual cycle management"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3005,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3006,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9268,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""67.1"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8378,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""45"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7945,"{""doseUnit"": ""MG"", ""route"": ""Intrathecal"", ""doseAmount"": ""12"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8990,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""120"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9269,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""210"", ""indication"": ""Osteoporosis postmenopausal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""180"", ""indication"": ""Lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7733,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9270,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""819"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8858,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""42"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""480"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7876,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9275,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9276,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1800"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7401,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""27"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7502,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Chronic myelomonocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41060,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9279,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Osteoporosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9141,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""COVID-19"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""70"", ""indication"": ""Migraine prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""5"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8812,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Hormone receptor negative HER2 positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9293,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.2"", ""indication"": ""Blood growth hormone abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8228,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""68"", ""indication"": ""Non-Hodgkin's lymphoma unspecified histology indolent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""8.4"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9299,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3.6"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8650,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""9800"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9300,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9301,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""350"", ""indication"": ""Non-small cell lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Myelodysplastic syndrome unclassifiable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9239,"{""doseUnit"": ""PCT"", ""route"": ""Cutaneous"", ""doseAmount"": ""5"", ""indication"": ""Back pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Mantle cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Hypercholesterolaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7179,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""65"", ""indication"": ""Fabry's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Other"", ""doseAmount"": ""0.279"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Oropharyngeal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8348,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1100"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8830,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9304,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Renal disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7995,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8870,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""225"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8622,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7818,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1075"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9044,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""193.25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8218,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""900"", ""indication"": ""Immune thrombocytopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9305,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Rhesus antigen negative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9306,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""600"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8859,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8621,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8670,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7537,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""631"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7440,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8247,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Deep vein thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7162,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""0.5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""52.5"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7955,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.25"", ""indication"": ""Insomnia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1440"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.3"", ""indication"": ""Allergy to arthropod sting"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7243,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.8"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9314,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""68"", ""indication"": ""Diffuse large B-cell lymphoma recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9315,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.1"", ""indication"": ""Peripheral arterial occlusive disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Embolism venous"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Monoclonal gammopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8353,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""80"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9297,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Thrombocytopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7255,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8172,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8773,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""60"", ""indication"": ""Osteoporosis postmenopausal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8247,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Major depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9031,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9322,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Eye infection toxoplasmal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9322,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Cerebral toxoplasmosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""64.5"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""84"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9327,"{""doseUnit"": ""PCT"", ""route"": ""Topical"", ""doseAmount"": ""5"", ""indication"": ""Myalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9329,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""882"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9333,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Adenomatous polyposis coli"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8911,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""80"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9297,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Thrombocytopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Polyneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8801,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""300"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8636,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""118.2"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7352,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""0.4"", ""indication"": ""Acute lymphocytic leukaemia recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8660,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""330"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8796,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""234"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Uveal melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7662,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""930"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9134,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8870,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""225"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8518,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Bone density decreased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Dementia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Pseudolymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7411,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9127,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9340,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""875"", ""indication"": ""Clostridium difficile infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7171,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""70"", ""indication"": ""Chronic graft versus host disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7298,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Pyrexia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8184,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Cystic fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9343,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2400"", ""indication"": ""Nasal congestion"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7432,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""250"", ""indication"": ""Renal transplant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3300,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8917,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""150"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Mantle cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7190,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.8"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Eczema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41284,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7832,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41289,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8353,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""801"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7586,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.25"", ""indication"": ""Atrial fibrillation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8451,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2.57"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41300,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.5"", ""indication"": ""Blood growth hormone abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.2"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.4"", ""indication"": ""Hypothalamo-pituitary disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7230,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Eczema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""204"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41311,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8483,"{""doseUnit"": ""ML"", ""route"": ""Other"", ""doseAmount"": ""100"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7255,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41318,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7411,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6000"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9127,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Philadelphia positive acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9297,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Thrombocytopenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9352,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Iron deficiency anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""70"", ""indication"": ""Migraine prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8773,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""60"", ""indication"": ""Osteoporosis postmenopausal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9353,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7918,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41338,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8932,"{""doseUnit"": ""IU"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Uterine leiomyoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9356,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8846,"{""doseUnit"": ""MCI"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Phaeochromocytoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41348,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.2"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.6"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1472"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""300"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9329,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""1064"", ""indication"": ""Schizoaffective disorder bipolar type"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41362,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9329,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""662"", ""indication"": ""Schizoaffective disorder depressive type"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7553,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""15"", ""indication"": ""Barrett's oesophagus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7955,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Subdermal"", ""doseAmount"": ""68"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7196,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""300"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""900"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7393,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""17"", ""indication"": ""Constipation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""56"", ""indication"": ""Depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8929,"{""doseUnit"": ""ML"", ""route"": ""Unknown"", ""doseAmount"": ""15"", ""indication"": ""Magnetic resonance imaging head"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8929,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""15"", ""indication"": ""Magnetic resonance imaging head"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Monoclonal gammopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8446,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41377,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""68"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""122"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous drip"", ""doseAmount"": ""75"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8929,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""11"", ""indication"": ""Magnetic resonance imaging"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""84"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""420"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Cardiomyopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8964,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Cervix cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8929,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Magnetic resonance imaging head"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8389,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""22"", ""indication"": ""Colonoscopy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41399,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""70"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""960"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8565,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""480"", ""indication"": ""Small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7220,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Anticoagulant therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9366,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""16"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9368,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""36"", ""indication"": ""Mucopolysaccharidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41414,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7359,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7356,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.6"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7469,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""162"", ""indication"": ""Juvenile idiopathic arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8353,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""267"", ""indication"": ""Idiopathic pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9031,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.5"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8655,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""7.5"", ""indication"": ""Chronic tonsillitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9183,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Irritable bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7432,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""250"", ""indication"": ""Strabismus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41429,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7432,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Immunosuppression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7432,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8622,"{""doseUnit"": ""KG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.2"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""ML"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.35"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7498,"{""doseUnit"": ""UG"", ""route"": ""Buccal"", ""doseAmount"": ""600"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41439,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9374,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""14"", ""indication"": ""Endometrial cancer recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41441,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9375,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""200"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9300,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Diarrhoea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Gastric cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.46"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8290,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""70"", ""indication"": ""Migraine prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41448,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41449,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Hypercholesterolaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41450,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41451,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41452,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41453,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41454,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41455,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41456,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41457,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41458,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41459,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41460,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41461,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1200"", ""indication"": ""Invasive breast carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41462,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9384,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Osteoporosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41463,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41464,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41465,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Brain neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41466,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41467,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9162,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Clear cell renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41468,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41469,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41470,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41471,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41472,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41473,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41474,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41475,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41476,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41477,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Intradermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41478,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41479,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41480,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41481,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41482,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41483,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41484,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41485,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41486,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41487,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41488,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7359,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41489,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41490,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41491,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41492,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41493,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41494,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41495,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41496,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41497,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41498,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41499,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41500,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41501,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41502,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41503,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41504,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41505,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41506,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41507,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41508,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8004,"{""doseUnit"": ""MG"", ""route"": ""Nasal"", ""doseAmount"": ""84"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41509,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41510,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Short stature"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41511,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9387,"{""doseUnit"": ""IU"", ""route"": ""Intramuscular"", ""doseAmount"": ""33"", ""indication"": ""Skin cosmetic procedure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41512,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41513,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41514,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41515,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41516,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41517,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41518,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9390,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Myeloproliferative neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41519,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7160,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41520,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41521,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41522,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41523,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41524,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7251,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""52.9"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41525,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41526,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""360"", ""indication"": ""Bladder cancer"", ""drugSequence"": ""5""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41527,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41528,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41529,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7945,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""12"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41530,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41531,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41532,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41533,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41534,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""120"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41535,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41536,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8622,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41537,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41538,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41539,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7162,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Drug withdrawal syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41540,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7165,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Blood pressure abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41541,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7165,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Blood pressure abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41542,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7165,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41543,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41544,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Diverticulitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41545,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8970,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41546,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9394,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41547,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41548,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8858,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""42"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41549,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8858,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""42"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41550,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8139,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""284"", ""indication"": ""Hereditary neuropathic amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41551,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7611,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""65"", ""indication"": ""Mucopolysaccharidosis IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41552,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Hyperphenylalaninaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41553,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9268,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""10"", ""indication"": ""Transitional cell cancer of the renal pelvis and ureter"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41554,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7997,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41555,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41556,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Throat clearing"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41557,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41558,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8774,"{""doseUnit"": ""ML"", ""route"": ""Parenteral"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41559,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41560,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7460,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41561,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41562,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41563,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""420"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41564,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9399,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""750"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41565,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9400,"{""doseUnit"": ""IU/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600000"", ""indication"": ""Neoplasm"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41566,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Vascular graft"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41567,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41568,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41569,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41570,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41571,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41572,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Hyperchlorhydria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41573,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41574,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41575,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41576,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Duodenal ulcer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41577,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41578,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7745,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41579,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41580,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9401,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.25"", ""indication"": ""Transitional cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41581,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41582,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9174,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Sickle cell disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41583,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41584,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41585,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41586,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41587,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41588,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41589,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Barrett's oesophagus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41590,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrointestinal disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41591,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41592,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41593,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41594,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41595,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41596,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41597,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41598,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41599,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41600,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41601,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41602,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41603,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41604,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41605,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41606,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41607,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41608,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8655,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""9"", ""indication"": ""Headache"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41609,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8243,"{""doseUnit"": ""UG"", ""route"": ""Transdermal"", ""doseAmount"": ""37.5"", ""indication"": ""Procedural pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41610,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9374,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41611,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9399,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41612,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9404,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""70"", ""indication"": ""Still's disease"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41613,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9091,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2400"", ""indication"": ""Gallbladder cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41614,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9038,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2500"", ""indication"": ""Anaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41615,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8389,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""12"", ""indication"": ""Colonoscopy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41616,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9091,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4490"", ""indication"": ""Cholangiocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41617,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41618,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Ankylosing spondylitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41619,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41620,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8565,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41621,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9390,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Myelofibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41622,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7611,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Mucopolysaccharidosis IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41623,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9407,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1100"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41624,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9407,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1900"", ""indication"": ""Phenylketonuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41625,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7197,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41626,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7197,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41627,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8240,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41628,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7197,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41629,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41630,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41631,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41632,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41633,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41634,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41635,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41636,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41637,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41638,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41639,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41640,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41641,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8154,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41642,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41643,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7951,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Ewing's sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41644,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8630,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Pollakiuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41645,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8630,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""60"", ""indication"": ""Pollakiuria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41646,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41647,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41648,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41649,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41650,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8340,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41651,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8247,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Persistent depressive disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41652,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""980.1"", ""indication"": ""Glioblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41653,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8592,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""120"", ""indication"": ""Computerised tomogram thorax"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41654,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41655,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Hyperchlorhydria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41656,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41657,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""180"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41658,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41659,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41660,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41661,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41662,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7243,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""549.9"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41663,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41664,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41665,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41666,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41667,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7218,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41668,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41669,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8047,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""700"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41670,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41671,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41672,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41673,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41674,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41675,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9425,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41676,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41677,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9426,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41678,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8483,"{""doseUnit"": ""ML"", ""route"": ""Other"", ""doseAmount"": ""100"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41679,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41680,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41681,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7788,"{""doseUnit"": ""MG/M**2"", ""route"": ""Unknown"", ""doseAmount"": ""400"", ""indication"": ""Hepatobiliary cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41682,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41683,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41684,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""450"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41685,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41686,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41687,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41688,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41689,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41690,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41691,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41692,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41693,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41694,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41695,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41696,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41697,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41698,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41699,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41700,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7394,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""34"", ""indication"": ""Parkinson's disease psychosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41701,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7332,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""12.5"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41702,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41703,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8619,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Inappropriate schedule of product administration"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41704,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41705,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8291,"{""doseUnit"": ""UG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""28"", ""indication"": ""B precursor type acute leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41706,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9430,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41707,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41708,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41709,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41710,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41711,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9038,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2000"", ""indication"": ""Haemochromatosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41712,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41713,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8401,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""20"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41714,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41715,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41716,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41717,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41718,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7767,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41719,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9431,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Diarrhoea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41720,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8906,"{""doseUnit"": ""ML"", ""route"": ""Oral"", ""doseAmount"": ""16.5"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41721,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8164,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""650"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41722,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41723,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9432,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.3"", ""indication"": ""Anaphylactic reaction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41724,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8855,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""650"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41725,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41726,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41727,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41728,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41729,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41730,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9434,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""35"", ""indication"": ""Neurofibromatosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41731,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41732,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7678,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""750"", ""indication"": ""Epilepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41733,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41734,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41735,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41736,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8197,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""240"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41737,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8224,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Uterine leiomyoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41738,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41739,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41740,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrointestinal disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41741,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41742,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9435,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""112"", ""indication"": ""Cystic fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41743,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41744,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41745,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41746,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7853,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41747,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41748,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8803,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""143"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41749,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41750,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41751,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""400"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41752,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9437,"{""doseUnit"": ""UG"", ""route"": ""Urethral"", ""doseAmount"": ""500"", ""indication"": ""Erectile dysfunction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41753,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8610,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41754,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41755,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41756,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41757,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7456,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41758,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41759,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7899,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Metastatic malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41760,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9095,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Renal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41761,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41762,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9438,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Schizoaffective disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41763,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41764,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41765,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41766,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41767,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41768,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41769,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41770,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41771,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Abdominal pain upper"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41772,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41773,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41774,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8848,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""360"", ""indication"": ""K-ras gene mutation"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41775,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41776,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41777,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41778,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7993,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41779,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9442,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41780,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41781,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""240"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41782,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41783,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41784,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8646,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""HER2 positive breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41785,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41786,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41787,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7171,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Graft versus host disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41788,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41789,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7924,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""26"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41790,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.75"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41791,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Deep vein thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41792,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41793,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8686,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""2"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41794,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41795,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41796,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41797,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41798,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41799,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41800,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41801,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Hyperchlorhydria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41802,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41803,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7611,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""50"", ""indication"": ""Mucopolysaccharidosis IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41804,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41805,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7863,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.075"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41806,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41807,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9101,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""120"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41808,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41809,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41810,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41811,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41812,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8167,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41813,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41814,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Hypercholesterolaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41815,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7365,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.5"", ""indication"": ""Deep vein thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41816,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9447,"{""doseUnit"": ""DF"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10000"", ""indication"": ""Infertility female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41817,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41818,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41819,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9450,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Parkinson's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41820,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Hodgkin's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41821,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9155,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""100"", ""indication"": ""Computerised tomogram abdomen"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41822,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41823,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastric ulcer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41824,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41825,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41826,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Bladder cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41827,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41828,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Follicular lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41829,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41830,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7503,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""120"", ""indication"": ""Thrombosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41831,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41832,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41833,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41834,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastric disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41835,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41836,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41837,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41838,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrointestinal disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41839,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41840,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41841,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7506,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41842,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9300,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Diarrhoea"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41843,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41844,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41845,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9454,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Genital herpes"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41846,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Juvenile idiopathic arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41847,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9455,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8"", ""indication"": ""Metastatic carcinoma of the bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41848,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41849,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Pleural mesothelioma malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41850,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41851,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9456,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Anxiety"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41852,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8906,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41853,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9187,"{""doseUnit"": ""DF"", ""route"": ""Respiratory (inhalation)"", ""doseAmount"": ""1"", ""indication"": ""Chronic obstructive pulmonary disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41854,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41855,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41856,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8218,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1000"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41857,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41858,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.6"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41859,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.5"", ""indication"": ""Hormone therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41860,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9459,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Hepatitis C"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41861,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8189,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""140"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41862,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41863,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41864,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41865,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9460,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1.4"", ""indication"": ""Sarcoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41866,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""315"", ""indication"": ""Glioblastoma multiforme"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41867,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41868,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9461,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Orthostatic hypotension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41869,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7965,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""90"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41870,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41871,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41872,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9471,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Major depression"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41873,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41874,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41875,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41876,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41877,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:3997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41878,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41879,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41880,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41881,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Blood cholesterol increased"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41882,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41883,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Prostate cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41884,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9475,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""19.25"", ""indication"": ""Thrombolysis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41885,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""250"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41886,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8399,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41887,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41888,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41889,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41890,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41891,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8622,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41892,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41893,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7291,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Basal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41894,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""5q minus syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41895,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41896,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9437,"{""doseUnit"": ""UG"", ""route"": ""Urethral"", ""doseAmount"": ""250"", ""indication"": ""Erectile dysfunction"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41897,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7984,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Chronic spontaneous urticaria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41898,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41899,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7683,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1400"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41900,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41901,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8950,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41902,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9479,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Acute myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41903,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41904,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41905,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8578,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""150"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41906,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9374,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""18"", ""indication"": ""Renal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41907,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41908,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41909,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8173,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41910,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41911,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Cardiac failure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41912,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41913,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41914,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6000"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41915,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41916,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1200"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41917,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41918,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41919,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41920,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8222,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41921,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41922,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41923,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8407,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""380"", ""indication"": ""Alcoholism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41924,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41925,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9148,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41926,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41927,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41928,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7571,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41929,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8076,"{""doseUnit"": ""UG"", ""route"": ""Intra-uterine"", ""doseAmount"": ""20"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41930,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41931,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41932,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7862,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Dermatitis atopic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41933,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41934,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9485,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""30"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41935,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41936,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Pulmonary embolism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41937,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41938,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7335,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Cerebrovascular accident prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41939,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41940,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8548,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41941,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9091,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4040"", ""indication"": ""Cholangiocarcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41942,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41943,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41944,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41945,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9487,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""11"", ""indication"": ""Pancreatic carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41946,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41947,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""UG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41948,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8557,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""100"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41949,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9489,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.5"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41950,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9239,"{""doseUnit"": ""PCT"", ""route"": ""Cutaneous"", ""doseAmount"": ""5"", ""indication"": ""Fracture pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41951,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""600"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41952,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41953,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41954,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41955,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41956,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9490,"{""doseUnit"": ""DF"", ""route"": ""Unknown"", ""doseAmount"": ""4"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41957,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41958,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8737,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""125"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41959,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41960,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41961,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41962,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41963,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41964,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7994,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41965,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9491,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""600"", ""indication"": ""Gastric cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41966,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9492,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""405"", ""indication"": ""Schizophrenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41967,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41968,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8838,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""400"", ""indication"": ""Psoriatic arthropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41969,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7944,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41970,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG/KG"", ""route"": ""Unknown"", ""doseAmount"": ""0.012"", ""indication"": ""Noonan syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41971,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7334,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Dermatomyositis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41972,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41973,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41974,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7901,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41975,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41976,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41977,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7668,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41978,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7863,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.025"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41979,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1400"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41980,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.92"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41981,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9300,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Irritable bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41982,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41983,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9156,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41984,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41985,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7477,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2.3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41986,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7685,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""6"", ""indication"": ""Neutropenia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41987,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Failure to thrive"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41988,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.4"", ""indication"": ""Failure to thrive"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41989,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9131,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""0.3"", ""indication"": ""Acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41990,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41991,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41992,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41993,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8671,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41994,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7392,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""4"", ""indication"": ""Hypereosinophilic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41995,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8950,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""31.25"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41996,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9494,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41997,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""413"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41998,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""240"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:41999,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9329,"{""doseUnit"": ""MG"", ""route"": ""Intramuscular"", ""doseAmount"": ""1064"", ""indication"": ""Bipolar disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42000,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8172,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Asthma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42001,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7863,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""0.037"", ""indication"": ""Hormone replacement therapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42002,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7782,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Pulmonary embolism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42003,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9497,"{""doseUnit"": ""MG"", ""route"": ""Transdermal"", ""doseAmount"": ""1"", ""indication"": ""Motion sickness"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42004,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42005,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8660,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""285"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42006,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7984,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Idiopathic urticaria"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42007,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9498,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Endometriosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42008,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42009,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Dyspepsia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42010,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7545,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Gastrooesophageal reflux disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42011,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42012,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9499,"{""doseUnit"": ""DF"", ""route"": ""Transplacental"", ""doseAmount"": ""1"", ""indication"": ""HIV infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42013,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42014,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42015,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8847,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""2"", ""indication"": ""Type 2 diabetes mellitus"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42016,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42017,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9500,"{""doseUnit"": ""DF"", ""route"": ""Dental"", ""doseAmount"": ""2"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42018,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9019,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""7"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42019,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7883,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""59"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42020,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.8"", ""indication"": ""Growth disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42021,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""15"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42022,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7734,"{""doseUnit"": ""MG/M**2"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""55"", ""indication"": ""Non-small cell lung cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42023,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8766,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.46"", ""indication"": ""Colitis ulcerative"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42024,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42025,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42026,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Colorectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42027,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7254,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.5"", ""indication"": ""Short-bowel syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42028,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8964,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""200"", ""indication"": ""Prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42029,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7332,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""35"", ""indication"": ""Philadelphia positive acute lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42030,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""5q minus syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42031,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8312,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""25"", ""indication"": ""Hallucination"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42032,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8762,"{""doseUnit"": ""DF"", ""route"": ""Subdermal"", ""doseAmount"": ""1"", ""indication"": ""Contraception"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42033,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42034,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42035,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8478,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42036,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""8"", ""indication"": ""Nephroblastoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42037,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7164,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""250"", ""indication"": ""Tremor"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42038,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42039,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7283,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42040,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7278,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Crohn's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42041,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42042,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8335,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Cardiomyopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42043,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9061,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Psoriasis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42044,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7356,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""8"", ""indication"": ""Hypertonic bladder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42045,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7262,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""800"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42046,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Trigeminal neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42047,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7687,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Acromegaly"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42048,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""3"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42049,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8506,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""0.33"", ""indication"": ""Mucopolysaccharidosis II"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42050,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42051,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42052,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9095,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Renal cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42053,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Back disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42054,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42055,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""2.25"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42056,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42057,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42058,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42059,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""500"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42060,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7315,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42061,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Post herpetic neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42062,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7305,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Cardiac hypertrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42063,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9527,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""250"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42064,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42065,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42066,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42067,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42068,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42069,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42070,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7160,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Astrocytoma, low grade"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42071,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""1200"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42072,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""225"", ""indication"": ""Spinal osteoarthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42073,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7206,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42074,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42075,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42076,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42077,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42078,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer female"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42079,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42080,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9538,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""6500"", ""indication"": ""Factor IX deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42081,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7525,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""12"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42082,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""16.8"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42083,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42084,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42085,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7478,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""50"", ""indication"": ""Gastrointestinal stromal tumour"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42086,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7496,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""600"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42087,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Alopecia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42088,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42089,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""300"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42090,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42091,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42092,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42093,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7874,"{""doseUnit"": ""IU"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""3000"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42094,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42095,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42096,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42097,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7191,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Narcolepsy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42098,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""1"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42099,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Polyneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42100,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""0.8"", ""indication"": ""Septo-optic dysplasia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42101,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Pain in extremity"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42102,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""75"", ""indication"": ""Radiculopathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42103,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Back disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42104,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42105,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42106,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Nerve injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42107,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7437,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""45"", ""indication"": ""Chronic myeloid leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42108,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7681,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Relapsing multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42109,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8066,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42110,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8176,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""149"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42111,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7576,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""10"", ""indication"": ""Hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42112,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Post herpetic neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42113,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Seizure"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42114,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7249,"{""doseUnit"": ""MG"", ""route"": ""Other"", ""doseAmount"": ""120"", ""indication"": ""Multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42115,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Diabetic neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42116,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42117,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8066,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Pancreatic carcinoma metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42118,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42119,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7452,"{""doseUnit"": ""G"", ""route"": ""Oral"", ""doseAmount"": ""8.4"", ""indication"": ""Hyperkalaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42120,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""5"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42121,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Lymphangioma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42122,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42123,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Complex regional pain syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42124,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42125,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""G"", ""route"": ""Vaginal"", ""doseAmount"": ""1"", ""indication"": ""Atrophic vulvovaginitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42126,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7940,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""754"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42127,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4281,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7940,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""570"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42128,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4282,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7874,"{""doseUnit"": ""IU"", ""route"": ""Intravenous drip"", ""doseAmount"": ""5600"", ""indication"": ""Factor VIII deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42129,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4283,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Migraine"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42130,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4285,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8176,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""95"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42131,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4286,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7235,"{""doseUnit"": ""G"", ""route"": ""Vaginal"", ""doseAmount"": ""0.5"", ""indication"": ""Genital labial adhesions"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42132,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4287,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""50"", ""indication"": ""Arthralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42133,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4288,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42134,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4290,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Polyneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42135,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4291,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""12"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42136,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4292,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8348,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""52"", ""indication"": ""Chemotherapy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42137,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4293,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Neuropathy peripheral"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42138,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4294,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8091,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""80"", ""indication"": ""Amyloidosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42139,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4295,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Fibromyalgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42140,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4296,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42141,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4297,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""100"", ""indication"": ""Nerve injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42142,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4298,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer recurrent"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42143,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4299,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7490,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Muscle disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42144,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4301,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Small fibre neuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42145,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4302,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7338,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Alopecia areata"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42146,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4303,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Nerve injury"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42147,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4304,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8176,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""111"", ""indication"": ""Diffuse large B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42148,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4305,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7646,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""140"", ""indication"": ""Dyslipidaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42149,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4306,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42150,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4307,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42151,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4308,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Other"", ""doseAmount"": ""100"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42152,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4309,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42153,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4310,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42154,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4312,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""300"", ""indication"": ""Neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42155,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4313,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8151,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1500"", ""indication"": ""Severe myoclonic epilepsy of infancy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42156,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4314,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42157,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4315,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7715,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Mycobacterium abscessus infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42158,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4316,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42159,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4317,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Polyneuropathy chronic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42160,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4319,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Unknown"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42161,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4320,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42162,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4321,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7914,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""4"", ""indication"": ""Incontinence"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42163,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4322,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42164,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4323,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Bacterial infection"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42165,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4324,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42166,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4325,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""42.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42167,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4326,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7361,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""11"", ""indication"": ""Rheumatoid arthritis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42168,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4327,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""500"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42169,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4328,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9599,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""550"", ""indication"": ""Non-small cell lung cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42170,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4329,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42171,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4330,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""75"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42172,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4331,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Headache"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42173,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4332,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8058,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""4476"", ""indication"": ""Alpha-1 antitrypsin deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42174,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4333,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42175,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4334,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42176,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4335,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42177,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4336,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8468,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""90"", ""indication"": ""Lung neoplasm malignant"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42178,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4337,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""300"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42179,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4339,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Pain"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42180,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4340,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""21"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42181,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4341,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8099,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""Hepatocellular carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42182,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4342,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer metastatic"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42183,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4343,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8098,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""7.5"", ""indication"": ""Vaginal haemorrhage"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42184,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4344,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42185,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4345,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7996,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""400"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42186,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4346,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42187,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4347,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""33"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42188,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4349,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7178,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""75"", ""indication"": ""Neuralgia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42189,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4350,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42190,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4351,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:9168,"{""doseUnit"": ""NG"", ""route"": ""Unknown"", ""doseAmount"": ""55"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42191,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4352,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42192,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4353,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42193,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4354,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42194,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4355,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8202,"{""doseUnit"": ""MG"", ""route"": ""Intravenous drip"", ""doseAmount"": ""25"", ""indication"": ""Prophylaxis"", ""drugSequence"": ""3""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42195,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4356,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""22.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42196,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4357,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""4"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42197,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4358,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""15"", ""indication"": ""Congenital hypogammaglobulinaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42198,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4359,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""60"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42199,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4360,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""3.2"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42200,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4361,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2000"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42201,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4363,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7288,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""2.5"", ""indication"": ""Congenital generalised lipodystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42202,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4364,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""10"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42203,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4365,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""MG/KG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1000"", ""indication"": ""Myasthenia gravis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42204,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4366,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42205,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4367,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42206,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4368,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8577,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Pulmonary fibrosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42207,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4369,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7904,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Still's disease"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42208,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4370,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""1.7"", ""indication"": ""Growth hormone deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42209,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4371,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42210,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4372,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8194,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""300"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42211,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4373,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""80"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42212,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4374,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42213,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4375,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42214,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4376,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8175,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42215,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4378,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""49.5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42216,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4379,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42217,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4380,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""420"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42218,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4381,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7912,"{""doseUnit"": ""ML"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""49.5"", ""indication"": ""Spinal muscular atrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42219,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4382,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42220,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4383,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42221,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4384,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7850,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""60"", ""indication"": ""Non-small cell lung cancer stage IV"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42222,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4385,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7961,"{""doseUnit"": ""UG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""50"", ""indication"": ""Hypoparathyroidism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42223,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4386,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42224,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4387,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42225,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4388,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42226,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4389,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""100"", ""indication"": ""Fallopian tube cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42227,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4390,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42228,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4391,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8340,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42229,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4392,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7536,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""840"", ""indication"": ""Colon cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42230,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4393,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42231,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4394,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""16"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42232,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4395,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""8"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42233,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4396,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7613,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""360"", ""indication"": ""Cervix carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42234,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4397,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""18"", ""indication"": ""Immunoglobulins abnormal"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42235,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4398,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42236,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4400,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""6"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42237,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4401,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""42"", ""indication"": ""Chronic inflammatory demyelinating polyradiculoneuropathy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42238,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4402,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7490,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""1"", ""indication"": ""Menopausal symptoms"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42239,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4403,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7416,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42240,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4404,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42241,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4405,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""35"", ""indication"": ""Selective IgG subclass deficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42242,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4406,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42243,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4407,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""200"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42244,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4408,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7688,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""160"", ""indication"": ""Hormone-refractory prostate cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42245,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4409,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""47.5"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42246,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4410,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""2900"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42247,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4411,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42248,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4412,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""20"", ""indication"": ""Immunodeficiency"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42249,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4413,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""45"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42250,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4414,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7280,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""125"", ""indication"": ""Breast cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42251,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4415,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8735,"{""doseUnit"": ""DF"", ""route"": ""Oral"", ""doseAmount"": ""2"", ""indication"": ""Ovarian cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42252,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4416,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8454,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Non-Hodgkin's lymphoma"", ""drugSequence"": ""2""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42253,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4417,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7979,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""60"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42254,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4418,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8419,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""1800"", ""indication"": ""Duchenne muscular dystrophy"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42255,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4419,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""60"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42256,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4420,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8454,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""40"", ""indication"": ""B-cell lymphoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42257,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4421,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7632,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""0.4"", ""indication"": ""Hypopituitarism"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42258,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4422,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7718,"{""doseUnit"": ""MG"", ""route"": ""Subcutaneous"", ""doseAmount"": ""300"", ""indication"": ""Immune system disorder"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42259,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4423,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8143,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Diabetes mellitus"", ""drugSequence"": ""6""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42260,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4424,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""30"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42261,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4425,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""25"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42262,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4426,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8350,"{""doseUnit"": ""MG/M**2"", ""route"": ""Subcutaneous"", ""doseAmount"": ""75"", ""indication"": ""Myelodysplastic syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42263,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4427,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Colorectal cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42264,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4428,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Unknown"", ""doseAmount"": ""1"", ""indication"": ""Blood immunoglobulin A"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42265,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4430,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42266,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4431,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8531,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""5"", ""indication"": ""Renal cell carcinoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42267,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4432,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7982,"{""doseUnit"": ""G"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""40"", ""indication"": ""Immunodeficiency common variable"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42268,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4433,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Squamous cell carcinoma of head and neck"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42269,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4434,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8321,"{""doseUnit"": ""IU"", ""route"": ""Subcutaneous"", ""doseAmount"": ""3000"", ""indication"": ""Hereditary angioedema"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42270,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4435,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""150"", ""indication"": ""Anaplastic thyroid cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42271,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4436,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7383,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""30"", ""indication"": ""Astrocytoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42272,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4437,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8253,"{""doseUnit"": ""MG"", ""route"": ""Intravenous (not otherwise specified)"", ""doseAmount"": ""312"", ""indication"": ""Relapsing-remitting multiple sclerosis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42273,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4438,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7790,"{""doseUnit"": ""G"", ""route"": ""Subcutaneous"", ""doseAmount"": ""12"", ""indication"": ""Primary immunodeficiency syndrome"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42274,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4440,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8204,"{""doseUnit"": ""MG"", ""route"": ""Unknown"", ""doseAmount"": ""500"", ""indication"": ""Endometrial cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42275,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4442,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7384,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""0.5"", ""indication"": ""Malignant melanoma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42276,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4443,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7176,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""25"", ""indication"": ""Plasma cell myeloma"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42277,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4444,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8934,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""400"", ""indication"": ""Synovitis"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42278,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4445,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8014,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""140"", ""indication"": ""Chronic lymphocytic leukaemia"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42279,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4446,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:7860,"{""doseUnit"": ""MG"", ""route"": ""Oral"", ""doseAmount"": ""20"", ""indication"": ""Bile duct cancer"", ""drugSequence"": ""1""}"
5:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:42280,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:4447,4:a4ea6acb-b5fc-4a33-a21a-e4f10b877c39:8775,"{""doseUnit"": ""UG"", ""route"": ""Oral"", ""doseAmount"": ""1000"", ""indication"": ""Pulmonary arterial hypertension"", ""drugSequence"": ""1""}"
